Positron emission tomography: Current role for diagnosis and therapy monitoring in oncology

Oncologist

Volumn 2, Issue 6, 1997, Pages 381-388

  Strauss, Ludwig G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Diagnosis; Drugs; FDG; Management; Positron emission tomography; Therapy

Indexed keywords

ALCOHOL; AMMONIA; CARBON 11; CISPLATIN; COPPER 62; CYTOSTATIC AGENT; DEOXYURIDINE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GLUTAMIC ACID; GLYCOPROTEIN P; METHIONINE; NITROGEN 13; OXYGEN 15; SEMICARBAZONE DERIVATIVE; THYMIDINE; TYROSINE; URIDINE; WATER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL PROTOCOL; COLORECTAL CANCER; DRUG ELIMINATION; DRUG LABELING; DRUG MONITORING; DRUG TRANSPORT; GLUCOSE METABOLISM; HUMAN; ISOTOPE LABELING; LUNG TUMOR; LYMPHOMA; MELANOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

EID: 0031444701     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.2-6-381     Document Type: Article

References (19)

1. Strauss LG, Conti P. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648.
2. Kontaxakis G. Maximum likelihood image reconstruction in positron emission tomography: convergence characteristics and stopping rules. Ph.D. Thesis, Rutgers University, 1996.
3. Delbeke D, Meyerowitz C, Lapidus RL et al. Optimal cutoff levels of F-18-fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47-52.
4. Kubota K. Cancer diagnosis with positron emission tomography (PET). Kakuigaku 1996;33:207-212.
5. Pruim J, Willemsen ATM, Molenaar WM et al. Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology 1995;197:221-226.
6. McLoud TC, Kosiuk JP, Templeton PA et al. CT in the staging of bronchiogenic carcinoma: update of analysis by correlative lymph node mapping and sampling. Radiology 1989;173(P):69.
7. Webb WR, Gatsonis CA, Zerhouni EA et al. Comparison of CT and MR imaging in lung cancer staging: preliminary results of the RDOG imaging study. Radiology 1989;173(P):69.
8. Lewis P, Griffin S, Marsden P et al. Whole-body (18)F-fluo-rodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265-1266.
9. Wahl RL, Quint LE, Greenough RL et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-377.
10. Bangerter M, Kocher F, Binder T et al. Total body positron emission tomography (PET) for staging and follow-up of lymphoma. Proc Annu Meet Am Soc Clin Oncol 1995;14:A1206.
11. Gritters LS, Francis IR, Zasadny KR et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-1427.
12. Gupta NC, Falk AL, Thorson AM et al. Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebr Med J 1993;78:30-35.
13. Laubenbacher C, Saumweber D, Wagner-Manslau C et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995;36:1747-1757.
14. Garcia JR, Kim EE, Wong FCL et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996;37:1476-1479.
15. Avril N, Dose J, Janicke F et al. Metabolic characterization of breast tumors with positron emission tomography using F-18-fluorodeoxyglucose. J Clin Oncol 1996;14:1848-1857.
16. Stollfuss JC, Glatting G, Friess H et al. 2-(Fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer value of quantitative image interpretation. Radiology 1995;195:339-344.
17. Dewan NA, Reeb SD, Gupta NC et al. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions: a comparative risk-benefit analysis. Chest 1995;108:441-446.
18. Eil A, Dimitrakopoulou-Strauss A, Tilgen W et al. Functional imaging with positron emission tomography in patients with malignant melanoma. Onkologie 1996;19:253-259.
19. Kahn D, Follett KA, Bushnell DL et al. Diagnosis of recurrent brain tumor: value of (201)T1 SPECT vs (18)F-fluorodeoxyglucose PET. Am J Roentgenol 1994;163:1459-1465.